Injured Saskatchewan workers and first responders with accepted PTSD (post-traumatic stress disorder) or chronic pain claims occasionally pursue ketamine-assisted therapy through the Saskatchewan Workers' Compensation Board (WCB Saskatchewan). Unlike WSIB Ontario's structured five-formulary listing or WCB Alberta's documented Pharmaceutical Ketamine and Esketamine procedure, WCB Saskatchewan has no formal published policy listing ketamine, esketamine, psilocybin, or MDMA. Coverage is reviewed on a strict case-by-case basis, and approval is not guaranteed. This article explains the regulatory landscape, the Bill 91 presumptive PTSD framework, the CPSS Non-Hospital Treatment Facility rules that shape ketamine delivery in the province, and how ATMA CENA supports compensable Saskatchewan workers through its coordinated care partnership in Saskatoon.

Key takeaways

WCB Saskatchewan has no formal listing for ketamine, esketamine, psilocybin, or MDMA. Claims involving these treatments are reviewed case-by-case under the board's general health-care benefits authority. Coverage is provisional and not guaranteed.

Saskatchewan's Bill 91 (The Workers' Compensation Amendment Act, 2016) creates a legal presumption that PTSD diagnosed in designated first responders is work-related, accelerating claim acceptance but not auto-approving any specific treatment.

The College of Physicians and Surgeons of Saskatchewan (CPSS) January 2021 position requires a CPSS-accredited Non-Hospital Treatment Facility (NHTF) for all parenteral ketamine routes (IV, IM, SQ). This is more restrictive than CPSA Alberta, which only requires an NSHF for IV.

Sublingual, oral, and intranasal ketamine carry lighter regulatory requirements in Saskatchewan but still require a prescriber working within their scope of practice.

Active Saskatchewan ketamine providers include The Linden Medical Centre Saskatoon (CPSS-accredited NHTF) and inpatient programs at Royal University Hospital and the Dubé Centre. There is no publicly funded outpatient psychiatric ketamine program in Saskatchewan.

The Saskatchewan Drug Plan lists Spravato (esketamine) as a non-benefit; the Exception Drug Status pathway is rarely approved.

ATMA CENA's Saskatchewan member clinic, Evolve Counselling and Wellness in Saskatoon, delivers ketamine-assisted therapy through coordinated care partnership.

What WCB Saskatchewan covers for psychedelic-assisted therapy

WCB Saskatchewan's general statutory authority allows the board to fund medical aid that is "necessary, appropriate, and sufficient" to treat a compensable injury. Unlike WSIB Ontario or WCB Alberta, the Saskatchewan board has not published a procedure, policy, or formulary listing specific to ketamine, esketamine, psilocybin, or MDMA. This means there is no documented pathway, no standard prior-authorization form, and no published clinical criteria that map workers to coverage [WCB Saskatchewan].

In practice, WCB Saskatchewan reviews ketamine and esketamine treatment requests case-by-case. The treating specialist submits clinical documentation, the board's medical advisors review the request, and a written decision is issued. Coverage is provisional. Workers and clinicians should not assume approval based on outcomes from neighbouring provinces.

Psilocybin and MDMA are not listed by WCB Saskatchewan and are highly unlikely to be funded in the current 2026 environment. These substances are restricted drugs under Canada's Controlled Drugs and Substances Act, and patient access is available only through Health Canada's Special Access Program (SAP) on a case-by-case basis. SAP approval is not guaranteed and approval rates declined significantly in 2025 [PsyCan 2025; Health Canada SAP].

Ketamine is approved by Health Canada as an anaesthetic. Use for PTSD, depression, anxiety, and chronic pain is off-label. Off-label prescribing is permitted in Canada but is regulated provincially. In Saskatchewan, oversight rests with the College of Physicians and Surgeons of Saskatchewan (CPSS).

For a cross-provincial comparison of workers' compensation coverage for psychedelic-assisted therapy, see the workers' compensation and psychedelic-assisted therapy guide for Canada and the insurance coverage guide for psychedelic-assisted therapy in Canada.

Bill 91 — Saskatchewan's presumptive PTSD legislation

Saskatchewan's Bill 91, The Workers' Compensation Amendment Act, 2016, established a legal presumption that PTSD diagnosed in designated first responders arose from their employment, unless the contrary is proven [Saskatchewan Bill 91 2016]. This shifted the burden of proof and accelerated WCB claim acceptance for the listed populations.

Designated workers under Bill 91

Saskatchewan's presumption covers workers in designated first-responder occupations, including:

Firefighters (full-time, part-time, and volunteer)
Police officers
Paramedics and emergency medical responders
Correctional officers
Volunteer first responders working under recognized emergency-services structures

The 2016 amendment positioned Saskatchewan as an early adopter among Canadian provinces, alongside Manitoba and Alberta, and established the framework that has since shaped how compensable PTSD claims are adjudicated for the province's first-responder workforce.

What Bill 91 does and does not do

What the legislation does:

Removes the burden on the worker to prove their PTSD is work-related.
Accelerates WCB Saskatchewan claim acceptance once a qualifying clinical diagnosis is documented.
Speeds access to general mental-health treatment funded by WCB once the claim is accepted.

What the legislation does not do:

It does not auto-approve any specific treatment, including ketamine-assisted therapy.
It does not create a published treatment pathway or formulary.
Each request for non-standard treatment, including ketamine, still requires individual review and clinical justification.

For workers outside the designated first-responder occupations, the standard route to a compensable PTSD claim remains available but requires documentation of work-relatedness through the regular WCB Saskatchewan adjudication process. For a deeper review of presumptive PTSD legislation across Canada, see first responder PTSD presumptive legislation in Canada.

How CPSS shapes WCB Saskatchewan ketamine claims

The College of Physicians and Surgeons of Saskatchewan published a position document on ketamine off-label use in January 2021 that materially shapes how ketamine is delivered in the province [CPSS 2021]. The position is more restrictive than its Alberta equivalent and is essential context for any Saskatchewan worker pursuing WCB-funded ketamine therapy.

The Non-Hospital Treatment Facility (NHTF) requirement

The CPSS January 2021 position requires that all parenteral routes of ketamine — intravenous (IV), intramuscular (IM), and subcutaneous (SQ) — be delivered in a CPSS-accredited Non-Hospital Treatment Facility (NHTF) [CPSS 2021]. This is a stricter standard than CPSA Alberta's March 2026 guidance, which restricts only IV ketamine to a Non-Surgical Health Facility (NSHF) and permits IM, SQ, oral, sublingual, and intranasal routes in qualifying community clinical settings.

For a worker pursuing WCB Saskatchewan coverage for parenteral ketamine, this means treatment must occur in a CPSS-accredited NHTF. Clinics that do not hold NHTF accreditation cannot legally administer IV, IM, or SQ ketamine in Saskatchewan, regardless of WCB funding decisions.

Lighter requirements for non-parenteral routes

Sublingual, oral, and intranasal ketamine carry lighter regulatory requirements under the CPSS 2021 position. These routes can be prescribed by a physician operating within their scope of practice and do not require NHTF accreditation. Esketamine (Spravato), administered intranasally under supervision, falls into this category from a route-of-administration perspective, but its coverage is shaped separately by drug-plan listing decisions.

Off-label framing

Ketamine is approved by Health Canada as an anaesthetic. Use for PTSD, depression, anxiety, and chronic pain is off-label. The CPSS 2021 position acknowledges off-label ketamine prescribing for psychiatric and pain indications and outlines the clinical and facility expectations that govern such prescribing in Saskatchewan.

How to pursue a WCB Saskatchewan claim for ketamine therapy

The pathway from compensable claim to ketamine treatment in Saskatchewan is unstructured compared with Ontario or Alberta, but it generally follows these stages [WCB Saskatchewan]:

Establish the compensable diagnosis. For designated first responders, Bill 91 presumptive eligibility accelerates this step. For other workers, the treating physician documents the work-relatedness of the PTSD or chronic pain diagnosis according to standard WCB Saskatchewan adjudication.
Document conventional treatment failures. The treating specialist records trials of standard-of-care treatments (pharmacotherapy, evidence-based psychotherapy such as CBT or EMDR, or other indicated modalities) that have not produced sufficient improvement.
Identify a qualified prescriber. For parenteral ketamine, the prescribing physician must work within a CPSS-accredited NHTF. For oral, sublingual, or intranasal ketamine, the prescriber must operate within their scope of practice and clinical knowledge.
Submit clinical documentation to WCB Saskatchewan. Because there is no standard form, the treating specialist submits a clinical letter and supporting documentation. The package should establish the compensable diagnosis, prior treatment failures, proposed treatment protocol, route of administration, facility accreditation status, and clinical rationale.
WCB medical review. WCB Saskatchewan's medical advisors review the request. Additional information or specialist opinions may be requested. Decisions are communicated in writing to both the worker and the treating specialist.
Approval is provisional. Even when approved, coverage may be limited to a defined treatment course, with reassessment required for continuation.
Treatment begins. If approved, treatment is delivered in a qualifying clinical setting under physician oversight and in compliance with CPSS standards.

If WCB denies the request, workers may appeal through WCB Saskatchewan's internal review and ultimately the Saskatchewan Workers' Compensation Board Appeal Tribunal. The Office of the Worker's Advocate provides free assistance to injured workers in Saskatchewan navigating the appeal process.

How ATMA CENA supports compensable Saskatchewan workers

ATMA CENA's Saskatchewan member clinic is Evolve Counselling and Wellness, located at 1022A 8th Street, Saskatoon, SK S7H 0R9. Ketamine-assisted therapy delivery operates through coordinated care partnership, which connects compensable workers with qualified medical and therapy teams in Saskatoon.

ATMA CENA's role for WCB Saskatchewan workers is as the clinical preparation and integration partner — not the funding decision-maker. WCB Saskatchewan adjudicates coverage, the treating specialist submits the clinical request, and ATMA CENA supports the worker through the three-phase model of psychedelic-assisted therapy.

In practice, ATMA CENA's clinical process for WCB-referred Saskatchewan workers includes:

Intake and screening: An ATMA CENA practitioner reviews clinical history, treatment records, and compensable diagnosis to confirm appropriateness for ketamine-assisted therapy and to support the treating physician's documentation package.
Coordination with existing treaters: ATMA CENA works alongside, not instead of, the worker's existing psychiatrist, psychologist, family physician, or counsellors. This is especially relevant for first responders with established WCB-affiliated mental-health relationships.
Treatment delivery via coordinated care: If WCB approves and the route requires a CPSS-accredited NHTF (for parenteral ketamine), coordinated care partnership coordinates delivery with an appropriately accredited Saskatoon facility. For non-parenteral routes, treatment can be delivered through the Evolve clinic with prescribing physician oversight.
Documentation support: ATMA CENA can prepare clinical documentation describing treatment history, rationale, and the three-phase psychedelic-assisted therapy model to support the treating specialist's WCB submission. ATMA CENA does not submit on behalf of the worker; only the treating physician does so.

For workers in Saskatoon and surrounding communities, psychedelic-assisted therapy in Saskatoon and ketamine therapy in Saskatoon are relevant local access points. For ketamine evidence specific to PTSD, see ketamine therapy for PTSD.

Saskatchewan first responders who are veterans of the Canadian Armed Forces or RCMP may also have access through Veterans Affairs Canada. See VAC coverage for psychedelic-assisted therapy for that pathway.

Other Saskatchewan ketamine providers

For context, other active ketamine providers in Saskatchewan include:

The Linden Medical Centre Saskatoon (200-149 Pacific Avenue): a CPSS-accredited NHTF offering IV ketamine infusions for psychiatric and pain indications. Psychiatrist Dr. Monika Hooper is associated with the program. Self-pay rates approximate $525 per IV session [Linden Medical Centre Saskatoon].
Royal University Hospital and the Dubé Centre for Mental Health (Saskatoon Health Region): inpatient mental-health programs, with some intranasal ketamine delivery for treatment-resistant depression among inpatients via the University of Saskatchewan psychiatric team.

There is no publicly funded outpatient psychiatric ketamine program in Saskatchewan as of 2026. The Saskatchewan Drug Plan lists Spravato (esketamine) as a non-benefit, and the Exception Drug Status pathway is rarely approved [Saskatchewan Drug Plan].

Frequently asked questions

Does WCB Saskatchewan cover psychedelic-assisted therapy?

WCB Saskatchewan has no formal listing or published policy for ketamine, esketamine, psilocybin, or MDMA. Claims involving these treatments are reviewed case-by-case under the board's general health-care benefits authority. Coverage is provisional and is not guaranteed. Approvals, when granted, are typically for ketamine and limited to a defined treatment course [WCB Saskatchewan].

Does Saskatchewan's Bill 91 automatically cover ketamine therapy?

No. Bill 91 (The Workers' Compensation Amendment Act, 2016) creates a presumption that PTSD diagnosed in designated first responders is work-related. This accelerates claim acceptance but does not automatically approve any specific treatment. A worker with a compensable PTSD claim still requires a separate clinical request and individual WCB review for ketamine-assisted therapy.

Who qualifies as a designated first responder under Saskatchewan's presumptive PTSD legislation?

Bill 91 designates firefighters (full-time, part-time, and volunteer), police officers, paramedics and emergency medical responders, correctional officers, and recognized volunteer first responders. Other Saskatchewan workers with PTSD claims must document work-relatedness through standard WCB adjudication.

Can ketamine be delivered anywhere in Saskatchewan?

No. The CPSS January 2021 position requires that all parenteral routes of ketamine — IV, IM, and SQ — be delivered in a CPSS-accredited Non-Hospital Treatment Facility (NHTF). This is more restrictive than Alberta, which only requires this for IV. Sublingual, oral, and intranasal ketamine carry lighter requirements and may be prescribed by a physician operating within scope of practice [CPSS 2021].

Does WCB Saskatchewan cover psilocybin or MDMA?

No. Psilocybin and MDMA are not listed by WCB Saskatchewan and are not realistically funded in the current 2026 environment. These substances are restricted drugs under Canada's Controlled Drugs and Substances Act. Patient access is available only through Health Canada's Special Access Program. SAP approval is not guaranteed and declined significantly in 2025 [PsyCan 2025; Health Canada SAP].

Can ATMA CENA submit my WCB Saskatchewan request on my behalf?

No. The clinical request must be submitted by a treating physician. ATMA CENA can prepare supporting clinical documentation describing treatment history, rationale, and the three-phase psychedelic-assisted therapy model, but only the treating specialist may submit the request to WCB Saskatchewan.

What if WCB Saskatchewan denies my request?

Workers can appeal through WCB Saskatchewan's internal review process and, if needed, the Saskatchewan Workers' Compensation Board Appeal Tribunal. The Office of the Worker's Advocate provides free assistance to injured workers navigating appeals. Additional clinical documentation, further evidence of treatment failures, and specialist consultation reports may strengthen an appeal.

Is Spravato (esketamine) covered in Saskatchewan?

The Saskatchewan Drug Plan lists Spravato (esketamine) as a non-benefit. The Exception Drug Status (EDS) pathway is rarely approved for Spravato. WCB Saskatchewan would review any request involving Spravato case-by-case, with no published precedent of routine approval [Saskatchewan Drug Plan].

How does ATMA CENA deliver ketamine-assisted therapy in Saskatchewan?

ATMA CENA's Saskatchewan member clinic is Evolve Counselling and Wellness (1022A 8th Street, Saskatoon). Ketamine-assisted therapy delivery operates through coordinated care partnership. For parenteral ketamine, treatment is coordinated with a CPSS-accredited NHTF. For non-parenteral routes, treatment can be delivered through the Evolve clinic with prescribing physician oversight.

What is the typical out-of-pocket cost if WCB does not approve coverage?

Ketamine treatment costs vary by provider, route, and protocol. Self-pay IV ketamine in Saskatoon is offered at approximately $525 per session at The Linden Medical Centre Saskatoon. Total program costs depend on the protocol length and whether psychotherapy preparation and integration are included. ATMA CENA discusses estimated self-pay costs during the intake call for workers whose WCB claim is denied or pending.

Compliance notes

Ketamine off-label framing

Ketamine is approved by Health Canada as an anaesthetic. Use for PTSD, depression, anxiety, and chronic pain is off-label and regulated in Saskatchewan by the College of Physicians and Surgeons of Saskatchewan (CPSS). The CPSS January 2021 position requires that all parenteral ketamine (IV, IM, SQ) be administered in a CPSS-accredited Non-Hospital Treatment Facility (NHTF). Sublingual, oral, and intranasal routes carry lighter requirements but must be prescribed by a physician operating within scope of practice [CPSS 2021]. All ketamine-assisted therapy delivered through ATMA CENA's Saskatchewan partnership is conducted under physician oversight and in compliance with current CPSS standards.

Psilocybin and MDMA framing

Psilocybin and MDMA are restricted drugs under Canada's Controlled Drugs and Substances Act. Accessed only through Health Canada's Special Access Program. SAP approval is granted on a case-by-case basis and is not guaranteed. Approval rates declined significantly in 2025 [PsyCan 2025; Health Canada SAP]. WCB Saskatchewan does not list psilocybin or MDMA on any benefit schedule and is not a realistic funding source for these substances under the current 2026 framework.

Sources

WCB Saskatchewan. Workers' Compensation Board of Saskatchewan — claims, benefits, and policy. https://www.wcbsask.com/
Government of Saskatchewan (2016). The Workers' Compensation Amendment Act, 2016 (Bill 91) — presumptive PTSD coverage for designated first responders. https://www.publications.gov.sk.ca/
College of Physicians and Surgeons of Saskatchewan (2021, January). Ketamine off-label use — CPSS position document. https://www.cps.sk.ca/iMIS/Documents/For%20Physicians/Advisories%20and%20Positions/2021.01.19%20Ketamine%20off-label%20use%20CPSS%20position%20document.pdf
College of Physicians and Surgeons of Saskatchewan. Non-Hospital Treatment Facility (NHTF) accreditation program. https://www.cps.sk.ca/
Health Canada (2022). Notice to stakeholders: Requests to the Special Access Program (SAP) involving psychedelic-assisted psychotherapy. https://www.canada.ca/en/health-canada/services/drugs-health-products/drug-products/announcements/requests-special-access-program-psychedelic-assisted-psychotherapy.html
Health Canada. Spravato (esketamine) Product Monograph. https://pdf.hres.ca/dpd_pm/00057268.PDF
PsyCan (2025). PsyCan Discovers Sharp Decline in Health Canada Approvals for Doctors Seeking Legal Psychedelic Therapy for Patients. https://psychedelicscanada.org/media/2025/09/psycan-discovers-sharp-decline-in-health-canada-approvals-for-doctors-seeking-legal-psychedelic-therapy-for-patients
Saskatchewan Ministry of Health. Saskatchewan Drug Plan Formulary and Exception Drug Status pathway. https://formulary.drugplan.ehealthsask.ca/
Feder, A. et al. (2023). A Randomized Controlled Trial of Repeated Ketamine Administration for Chronic Posttraumatic Stress Disorder. American Journal of Psychiatry. https://pubmed.ncbi.nlm.nih.gov/37404970/
Mitchell, J.M. et al. (2023). MDMA-assisted therapy for moderate to severe PTSD: a randomized, placebo-controlled phase 3 trial. Nature Medicine, 29(10), 2473–2480. https://pubmed.ncbi.nlm.nih.gov/37709999/
Mithoefer, M.C. et al. (2018). 3,4-methylenedioxymethamphetamine (MDMA)-assisted psychotherapy for PTSD in military veterans, firefighters, and police officers. Lancet Psychiatry. https://pubmed.ncbi.nlm.nih.gov/29728331/
The Linden Medical Centre Saskatoon. Ketamine infusion therapy program. 200-149 Pacific Avenue, Saskatoon, SK. https://www.lindenmedicalcentre.ca/

Workers' Compensation and Psychedelic-Assisted Therapy in Canada — cross-provincial comparison
Insurance Coverage for Psychedelic-Assisted Therapy in Canada — private and group insurance coverage overview
WCB Alberta Psychedelic Therapy — Alberta's formal prior-authorization procedure
WSIB Coverage for Psychedelic-Assisted Therapy in Ontario — Ontario's formulary-based coverage framework
First Responder PTSD Presumptive Legislation in Canada — national comparison of presumptive PTSD coverage
VAC Coverage for Psychedelic-Assisted Therapy — veterans pathway
Ketamine Therapy for PTSD — PTSD evidence deep-dive
Psychedelic-Assisted Therapy in Saskatoon — local hub
Ketamine Therapy in Saskatoon — Saskatoon ketamine therapy access

Last updated: 2026-05-06. This article is reviewed every 3 months given time-sensitive regulatory and coverage information.

WCB Saskatchewan and Psychedelic-Assisted Therapy: Coverage and the Case-by-Case Pathway (2026)

Coverage rules differ by payer